Literature DB >> 2554921

Effects of selective inhibitors on cyclic nucleotide phosphodiesterases of rabbit aorta.

H S Ahn1, W Crim, M Romano, E Sybertz, B Pitts.   

Abstract

In this study three forms of cyclic nucleotide phosphodiesterase (PDE) isolated from rabbit aorta were pharmacologically characterized, and the consequence of selective inhibition of calmodulin-stimulated PDE (CaM-PDE) and cGMP specific PDE (cG-PDE) was evaluated using PDE inhibitors. The cG-PDE (F1) was selectively inhibited by M&B 22948 (IC50 = 0.5 microM) and dipyridamole (IC50 = 7 microM). The cAMP-PDE (cA-PDE, F3) was inhibited more effectively by the cA-PDE inhibitor milrinone than by other PDE inhibitors. The cA-PDE preparation appeared to contain both cG-inhibited PDE and cG-insensitive PDE based on an additive inhibition of the activity by milrinone and SQ 65442, respective inhibitors of these enzymes. Vinpocetine, 8-methoxymethyl isobutylmethylxanthine (8-MeOMeMIX) and M&B 22948 effectively inhibited CaM-PDE (F2). Vinpocetine was a more selective inhibitor of CaM-PDE than M&B 22948 or 8-MeOMeMIX. CaM-PDEs isolated from rabbit aorta and bovine brain exhibited a similar sensitivity to these inhibitors. Seventy-two percent of the cGMP-hydrolyzing activity of this rabbit aortic CaM-PDE preparation was immunoadsorbed to monoclonal antibody (ACC-1) against CaM bound to brain CaM-PDE. Vinpocetine, 8-MeOMeMIX and M&B 22948 at concentrations (30 and 100 microM) which inhibit CaM-PDE greater than 60% increased cGMP but not cAMP levels in l-norepinephrine (NE) preincubated rabbit aortic slices. At concentrations selectively inhibiting cG-PDE, dipyridamole and M&B 22948 increased cGMP levels in untreated slices but failed to increase cGMP levels significantly in NE-treated slices. By contrast, vinpocetine failed to increase cGMP significantly in untreated slices, although it increased cGMP levels in NE or KCl preincubated slices. These data indicate that, in activated (precontracted) aorta, CaM-PDE is a major enzyme, whereas in untreated aorta cG-PDE is a predominant enzyme for the hydrolysis of cGMP. This study also shows a usefulness of selective inhibitors in identifying different forms of PDE and similar drug sensitivities and immunoadsorption of aortic and brain CaM-PDEs by a monoclonal antibody.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2554921     DOI: 10.1016/0006-2952(89)90631-x

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  26 in total

Review 1.  Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments.

Authors:  Thérèse Keravis; Claire Lugnier
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

Review 2.  Cyclic nucleotide phosphodiesterases as targets for treatment of haematological malignancies.

Authors:  Adam Lerner; Paul M Epstein
Journal:  Biochem J       Date:  2006-01-01       Impact factor: 3.857

3.  Decreased cGMP level contributes to increased contraction in arteries from hypertensive rats: role of phosphodiesterase 1.

Authors:  Fernanda R Giachini; Victor V Lima; Fernando S Carneiro; Rita C Tostes; R Clinton Webb
Journal:  Hypertension       Date:  2011-01-31       Impact factor: 10.190

Review 4.  An update on vinpocetine: New discoveries and clinical implications.

Authors:  Yi-Shuai Zhang; Jian-Dong Li; Chen Yan
Journal:  Eur J Pharmacol       Date:  2017-11-26       Impact factor: 4.432

Review 5.  Anti-platelet therapy: phosphodiesterase inhibitors.

Authors:  Paolo Gresele; Stefania Momi; Emanuela Falcinelli
Journal:  Br J Clin Pharmacol       Date:  2011-10       Impact factor: 4.335

6.  Nitric oxide hyperpolarizes rabbit mesenteric arteries via ATP-sensitive potassium channels.

Authors:  M E Murphy; J E Brayden
Journal:  J Physiol       Date:  1995-07-01       Impact factor: 5.182

Review 7.  Isoenzyme selective phosphodiesterase inhibitors: potential clinical uses.

Authors:  I P Hall
Journal:  Br J Clin Pharmacol       Date:  1993-01       Impact factor: 4.335

8.  The antiarrhythmic effects of the nucleoside transporter inhibitor, R75231, in anaesthetized pigs.

Authors:  C L Wainwright; J R Parratt; H Van Belle
Journal:  Br J Pharmacol       Date:  1993-06       Impact factor: 8.739

9.  Studies of the nucleoside transporter inhibitor, draflazine, in the human myocardium.

Authors:  M Böhm; C Weinhold; R H Schwinger; J Müller-Ehmsen; D Böhm; H Reichenspurner; B Reichart; E Erdmann
Journal:  Br J Pharmacol       Date:  1994-05       Impact factor: 8.739

Review 10.  Targeting phosphodiesterases in anti-platelet therapy.

Authors:  Matthew T Rondina; Andrew S Weyrich
Journal:  Handb Exp Pharmacol       Date:  2012
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.